HRAS and head and neck squamous cell carcinoma: Based on this encouraging clinical activity, an international, multi-center, open-label, single-arm, pivotal study of tipifarnib after failure of platinum-based therapy in recurrent or metastatic HNSCC with HRAS mutations, AIM-HN, is under way (NCT03719690).